AbbVie, Bristol Myers Squibb, and Novartis have filed separate lawsuits in Illinois, each seeking to overturn a recently ...

Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...

A kidney transplant patient with a rare, multidrug-resistant (MDR) infection has become the first to be treated using an adjunctive bacteriophage therapy developed by Denmark's SNIPR Biome. The ...

Lilly has filed six new lawsuits – naming US companies Aesthetic Envy, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide as defendants – alleging they are selling ...

A therapy room used to deliver the one-off, therapist-assisted treatment. Psychedelic drug developer Definium Therapeutics has reported positive phase 3 results with its LSD-based therapy, DT120, in ...

Insmed is joining forces with an organisation representing people living with the chronic lung disorder bronchiectasis to carry out a large-scale, real-world study of its recently approved therapy ...

The US regulator has sent a complete response letter (CRL) to Germany-based ITM, saying there are deficiencies in its chemistry, manufacturing and controls (CMC) in its New Drug Application (NDA) for ...

Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...

The FDA has approved AbbVie's Decnupaz, a treatment for rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) that was one of the assets in its $10.1 billion takeover of ImmunoGen in ...

US President Donald Trump has signed an executive order that rips up the current US policy on childhood immunisations, ...

Dame Emma Walmsley has been CEO at GSK since 2017. This week has kicked off with the unexpected news that Emma Walmsley is standing down as chief executive of GSK after eight years, to be replaced by ...

Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial. The REACH-DMD study of pizuglanstat ...